arrow
Return

Combinatorial Fc modifications for complementary antibody functionality

delete2025-02-14
delete0
delete
OA
AI
Y
Yannic C. Bartsch *
N
Nicholas E. Webb *
E
Eleanor Burgess
J
Jaewon Kang
D
Douglas A. Lauffenburger
B
Boris Jülg *
DOI:10.1080/19420862.2025.2465391delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Therapeutic monoclonal antibodies (mAbs) can be functionally enhanced via Fc engineering. To determine whether pairs of mAbs with different Fc modifications can be combined for functional complementarity, we investigated the in vitro activity of two HIV-1 mAb libraries, each equipped with 60 engineered Fc variants. Our findings demonstrate that the impact of Fc engineering on Fc functionality is dependent on the specific Fab clone. Notably, combinations of Fc variants of the same Fab specificity exhibited limited enhancement in functional breadth compared to combinations involving two distinct Fabs. This suggests that the strategic selection of complementary Fc modifications can enhance both functional activity and breadth. Furthermore, while some combinations of Fc variants displayed additive functional effects, others were detrimental, suggesting that the functional outcome of Fc mutations is not easily predicted. Collectively, these results provide preliminary evidence supporting the potential of complementary Fc modifications in mAb combinations. Future studies will be essential to identify the optimal Fc modifications that maximize in vivo efficacy.
Keywords:
Broadly functional antibodies
complimentary combinations
Fc-modifications
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

mAbs cover
mAbs
IF:
7.3
Papers:
1.8K
Citations:
7.2K

Organization

A
a ragon institute of mass general
Scholars:
5
Papers: 1
Citations: 0
M
Massachusetts Institute of Technology
Scholars:
2.4K
Papers: 1.1K
Citations: 8
Cited Papers

Cited Papers

Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2
err2023-04-03
err0
errOAAI
errSamantha R. Mackin; Pritesh Desai; Bradley M. Whitener; Courtney E. Karl; Meizi Liu; Ralph S. Baric; Darin K. Edwards; Taras M. Chicz; Ryan P. McNamara; Galit Alter; Michael S. Diamond
errShare
errSave
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
err2011-03-01
err0
errOAAI
errMargaret E. Ackerman; Brian Moldt; Richard T. Wyatt; Anne-Sophie Dugast; Elizabeth McAndrew; Stephen Tsoukas; Stephanie Jost; Christoph T. Berger; Gaia Sciaranghella; Qingquan Liu; Darrell J. Irvine; Dennis R. Burton; Galit Alter
errShare
errSave
Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022
err2021-01-11
err30
errOAAI
errAtyeo, Caroline; Slein, Matthew D.; Fischinger, Stephanie; Burke, John; Schafer, Alexandra; Leist, Sarah R.; Kuzmina, Natalia A.; Mire, Chad; Honko, Anna; Johnson, Rebecca; Storm, Nadia; Bernett, Matthew; Tong, Pei; Zuo, Teng; Lin, Junrui; Zuiani, Adam; Linde, Caitlyn; Suscovich, Todd; Wesemann, Duane R.; Griffiths, Anthony; Desjarlais, John R.; Juelg, Boris D.; Goudsmit, Jaap; Bukreyev, Alexander; Baric, Ralph; Alter, Galit
errShare
errSave
Increasing the affinity of a human IgG1, for the neonatal Fc receptor: Biological consequences
err2002-11-01
err691
errOAAI
errDall'Acqua, WF; Woods, RM; Ward, ES; Palaszynski, SR; Patel, NK; Brewah, YA; Wu, H; Kiener, PA; Langermann, S
errShare
errSave
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
err2000-04-15
err1.3K
errOAAI
errIdusogie, EE; Presta, LG; Gazzano-Santoro, H; Totpal, K; Wong, PY; Ultsch, M; Meng, YG; Mulkerrin, MG
errShare
errSave
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies
err2008-09-01
err309
PREAI
errChu, Seung Y.; Vostiar, Igor; Karki, Sher; Moore, Gregory L.; Lazar, Greg A.; Pong, Erik; Joyce, Patrick F.; Szymkowski, David E.; Desjarlais, John R.
errShare
errSave
Fc-engineered antibodies promote neutrophil-dependent control of Mycobacterium tuberculosis
err2024-08-22
err0
errOAAI
errEdward B. Irvine; Angel Nikolov; Mehak Z. Khan; Joshua M. Peters; Richard Lu; Jaimie Sixsmith; Aaron Wallace; Esther van Woudenbergh; Sally Shin; Wiktor Karpinski; Jeff C. Hsiao; Arturo Casadevall; Bryan D. Bryson; Lisa Cavacini; Patricia S. Grace; Galit Alter; Sarah M. Fortune
errShare
errSave
Engineered antibodies with increased activity to recruit complement
err2001-02-15
err549
errOAAI
errIdusogie, EE; Wong, PY; Presta, LG; Gazzano-Santoro, H; Totpal, K; Ultsch, M; Mulkerrin, MG
errShare
errSave
Designing antibodies as therapeutics
errCell
IF0
err2022-07-01
err0
errOAAI
errPaul J. Carter; Arvind Rajpal
errShare
errSave
A One Pot, One Step, Precision Cloning Method with High Throughput Capability
err2008-11-05
err0
errOAAI
errCarola Engler; Romy Kandzia; Sylvestre Marillonnet
errShare
errSave
researcher View more